Provided by Tiger Trade Technology Pte. Ltd.

JPMORGAN HEALTHCARE LEADERS ETF

60.50
0.0000
Volume:11
Turnover:662.21
Market Cap:9.08M
PE:- -
High:60.50
Open:60.50
Low:60.50
Close:60.50
52wk High:64.69
52wk Low:50.40
Shares:150.00K
Float Shares:150.00K
Volume Ratio:0.15
T/O Rate:0.01%
Dividend:0.51
Dividend Rate:0.85%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly CEO tells Bloomberg sees more deals in untapped areas

TIPRANKS
·
Sep 29

Robert Hunter in Linkedin Post Says Stepping into New Role as President of Unitedhealthcare

THOMSON REUTERS
·
Sep 29

Lawyers in Alabama's TikTok Settlement Set to Earn $14 Million

Reuters
·
Sep 29

Teva Pharmaceutical's Duvakitug Could be Validated by Merck's Tulisokibart Results, Oppenheimer Says

MT Newswires Live
·
Sep 28

US Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 28

Johnson & Johnson (JNJ) Gets a Buy from Scotiabank

TIPRANKS
·
Sep 28

FDA Approves AbbVie’s JUVMO for Adults with Parkinson’s Disease

Reuters
·
Sep 28

U.S. FDA Approves Abbvie's Juvmo™ (Tavapadon) for Parkinson's Disease

THOMSON REUTERS
·
Sep 28

Abbvie - Juvmo Expected to be Available in the U.S. in October 2026

THOMSON REUTERS
·
Sep 28

Eli Lilly price target raised to $1,500 from $1,400 at JPMorgan

TIPRANKS
·
Sep 28

Merck in License Pact Worth up to $2.13 Billion with SciBrunch Therapeutics

Dow Jones
·
Sep 28

Lilly Launches Initiative to Expand Diabetes, Obesity Drug Access

MT Newswires Live
·
Sep 28

Eli Lilly launches ‘Lilly Change the Course Commitment’

TIPRANKS
·
Sep 28

Merck enters global license agreement with SciBrunch Therapeutics for SPR2015

TIPRANKS
·
Sep 28

Merck Enters into Exclusive Global License Agreement with Scibrunch Therapeutics for Spr2015, an Investigational Oral Kras G12d (On) Inhibitor

Reuters
·
Sep 28

Eli Lilly - to Register Diabetes and Obesity Medicines in Lmics and Expand Access

THOMSON REUTERS
·
Sep 28

Eli Lilly - Aims to Treat Equal Number of Patients in Lmics and High-Income Countries by 2040

THOMSON REUTERS
·
Sep 28

Merck & Co - to Record $400 Mln Pre-Tax Charge, $0.13 Per Share, in Q3 2026

THOMSON REUTERS
·
Sep 28

Merck & Co - Deal Includes $400 Mln Upfront, Total Potential Value $2.13 Bln; Deal Closed

THOMSON REUTERS
·
Sep 28

Merck & Co Inc: Under Agreement, Scibrunch Granted Co Exclusive Rights to Develop, Manufacture & Commercialize Spr2015 Worldwide

THOMSON REUTERS
·
Sep 28